Pfizer hasn’t delivered conclusive proof to back up its confidence on the value of booster shots in fighting COVID variants.
Rural health care has increasingly become a focus for the Trump administration as COVID-19 kills hundreds of Americans every day.
President Donald Trump’s new budget proposal flirts with combating high prescription drug prices, but industry watchers say the tweaks to Medicare and Medicaid do little more than dance around the edges of lowering the actual prices of drugs.
Medicare enrollees, who have watched their out-of-pocket spending on prescription drugs climb in recent years, might be in for a break. Federal officials are exploring how beneficiaries could get a share of certain behind-the-scenes fees and discounts negotiated by insurers and pharmacy benefit managers, or PBMs, who together administer Medicare’s Part D drug program.